ESR1 and breast neoplasm: This NSG-Pro model enables a 15- to 20-fold improvement in engraftment rates of therapy-naïve ER+ breast tumors and faithfully recapitulates the transition of these tumors to spontaneously metastatic and therapy-resistant disease.